Every minute, a child under five dies from malaria. While Lumefantrine remains a cornerstone in first-line treatment, its poor solubility and dependence on dietary fats severely limit therapeutic exposure in children—particularly in fasting or malnourished conditions.
Corealis Pharma, in collaboration with Rondol Industrie and Institut Jean Lamour, investigated the use of Vertical Hot Melt Extrusion (VHME) to produce amorphous solid dispersions (ASDs) of Lumefantrine. The study demonstrated a six-fold increase in dissolution, enhanced flowability, and robust stability under stress conditions, confirming VHME as a viable, scalable, and energy-efficient platform for developing child-friendly antimalarial formulations.
Download Whitepaper hot melt extrusion pdf
Contact Corealis
Corealis’ experts are ready to answer any queries about the company’s oral solid dose offering, including its development and manufacturing capabilities.
